Nootropic peptides on TikTok: separating hype from evidence

What did @b.louden06 actually say?

The creator called TAK-653 a "positive aesthetic modulator of the AMP-A receptors" that enhances glutamate signaling, improves learning and cognitive clarity, and passed phase two trials for depression. They also claimed it promotes neuroplasticity and can help "rewire habits," but warned it could backfire if someone reinforces bad habits. On that basis, TAK-653 earned the top spot on their nootropic tier list.

A few things to unpack immediately: the term "aesthetic modulator" is almost certainly a mispronunciation of "allosteric modulator," and "AMP-A" should be AMPA. Those are phonetic slip-ups, not scientific errors, but they matter when you're trying to evaluate credibility. The more substantive claims, the clinical trial reference and the neuroplasticity angle, deserve real scrutiny.

Does the science back this up?

Partially, yes. TAK-653 is a legitimate investigational compound, and it did advance into phase two trials for major depressive disorder. But the results were more complicated than "passed."

TAK-653 is an AMPA receptor positive allosteric modulator (PAM), a class of compounds that enhance glutamate-driven synaptic transmission without directly activating the receptor. The mechanism is real and well-studied. AMPA PAMs have been shown to increase BDNF expression and support long-term potentiation, both of which are tied to synaptic plasticity (Lynch et al., 2014, Pharmacological Reviews).

The phase two data on TAK-653 specifically is less triumphant than the video implies. A 2022 trial published in Neuropsychopharmacology (Atkinson et al.) found signals of antidepressant activity, but the trial was small, short-duration, and the compound has not received regulatory approval. Describing this as simply "passing" phase two overstates where the science actually sits.

On cognitive enhancement in healthy people, the evidence is essentially nonexistent. Almost all TAK-653 research targets treatment-resistant depression, not optimization in neurotypical individuals.

What did they get wrong (or right)?

Credit where it's due: the core mechanism description is directionally correct. AMPA PAMs do enhance glutamate signaling efficiency, and there is credible preclinical literature supporting improvements in memory consolidation and learning in animal models (Arai and Kessler, 2007, Current Drug Targets).

The "neuroplasticity" framing also has real backing. AMPA receptor upregulation is associated with BDNF-TrkB signaling cascades that support synaptic remodeling. So the creator isn't making that up.

Where things go sideways: the claim that TAK-653 can help you "rewire habits to become a better version of yourself" is speculative self-help framing dressed in neuroscience language. There are no human studies showing TAK-653 accelerates habit formation in healthy adults. None. The habit-rewiring framing is unsupported and, frankly, irresponsible because it implies a performance benefit the compound has not demonstrated outside of depression research.

The phase two framing is also misleading. Passing phase two does not mean a drug is validated or safe for off-label use. It means it cleared a preliminary efficacy bar in a controlled trial population, usually patients, not biohackers.

What should you actually know?

TAK-653 is not approved by the FDA or any major regulatory body. It is not available as a licensed medication, and it is not a regulated compounded peptide. Anyone selling it is operating outside pharmaceutical oversight, which means purity, dosing accuracy, and safety data are not guaranteed.

AMPA PAMs as a class carry real risk considerations. Excessive glutamate signaling is associated with excitotoxicity, the process by which neurons can be overstimulated to the point of damage (Bhatt et al., 2020, Frontiers in Pharmacology). That does not mean TAK-653 causes excitotoxicity at typical doses, but it means the "can backfire" warning the creator gives for bad habits dramatically understates the actual risk calculus.

If you're interested in cognitive enhancement, the compound landscape for healthy individuals is thin on rigorous human evidence. The most studied nootropics with safety profiles in healthy adults remain caffeine, creatine, and certain B vitamins. TAK-653 is not in that category.

• TAK-653 is an investigational drug, not a supplement or approved therapeutic.
• Phase two completion does not equal safety approval for general use.
• No human evidence supports cognitive enhancement in neurotypical adults.
• Glutamate modulation carries class-level risks that warrant caution.
• Anyone sourcing this compound is doing so without regulatory oversight of the product they're getting.